Cited by 1,309Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Open access

Garon, Edward B, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N, Goksel, Tuncay, Park, Keunchil, Gorbunova, Vera, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Czyzewicz, Grzegorz, Orlov, Sergey V, Lewanski, Conrad R, Thomas, Michael, Bidoli, Paolo, Dakhil, Shaker, Gans, Steven, Kim, Joo-Hang, Grigorescu, Alexandru, Karaseva, Nina, Reck, Martin, Cappuzzo, Federico, Alexandris, Ekaterine, Sashegyi, Andreas, Yurasov, Sergey, Pérol, Maurice·2014·The Lancet

DOI 10.1016/s0140-6736(14)60845-x

Open this paper in CoChat — free account

Abstract

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60845-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citation
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948

Show all 35 references

Research works printed but not linked: 1

Wilke, 2014, J Clin Oncol, 32

Sorted by citations

Items 101–200 of 1,001

Systemic treatment of brain metastases in non-small cell lung cancer
Page, S., Milner-Watts, C., Perna, M., Janžič, U., Vidal, N., Kaudeer, N., Ahmed, M., McDonald, F., Locke, I., Minchom, A. R., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.006 · Cited by 121
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 120
Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021) · Cancers · doi:10.3390/cancers13174444 · Cited by 128
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
Yoneshima, Y., Morita, S., Ando, M., Nakamura, A., Iwasawa, S., Yoshioka, H., Gotô, Y., Takeshita, M., Harada, T., Hirano, K., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.027 · Cited by 114
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
Arjaans, M., Schroder, C. P., Oosting, S. F., Dafni, U. G., Kleibeuker, J. E., & de Vries, E. G. E. (2016) · Oncotarget · doi:10.18632/oncotarget.6918 · Cited by 116
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
Yang, Y., Zhang, Y., Iwamoto, H., Hosaka, K., Seki, T., Andersson, P., Lim, S., Fischer, C., Nakamura, M., Abe, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12680 · Cited by 114
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Tran, H. T., Gibbons, D. L., Heeke, S., Fossella, F. V., Lam, V. K. L., Le, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.006 · Cited by 112
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study
Reck, M., Taylor, F. C., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H. B., Orsini, L. S., & Gralla, R. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.029 · Cited by 111
Self-citation
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.09 · Cited by 110
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Yoh, K., Hosomi, Y., Kasahara, K., Yamada, K., Takahashi, T., Yamamoto, N., Nishio, M., Ohe, Y., Koue, T., Nakamura, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.019 · Cited by 110
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Cho, B. C., Kim, D., Spira, A. I., Gomez, J. E., Haura, E. B., Kim, S., Sanborn, R. E., Cho, E. K., Lee, K. H., Minchom, A. R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02554-7 · Cited by 110
Self-citation
Repurposing itraconazole as an anticancer agent
Tsubamoto, H., Ueda, T., Inoue, K., Sakata, K., Shibahara, H., & Sonoda, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.6325 · Cited by 107
Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer
Javle, M. M., Smyth, E. C., & Chau, I. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1071 · Cited by 106
An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages
Mahdavi, S. Z. B., Oroojalian, F., Eyvazi, S., Hejazi, M., Baradaran, B., Pouladi, N., Tohidkia, M. R., Mokhtarzadeh, A., & Muyldermans, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.113 · Cited by 115
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
Herbst, R. S., Baas, P., Perez‐Gracia, J. L., Felip, E., Kim, D.-W., Han, J., Molina, J. R., Kim, J. H., Arvis, C. D., Ahn, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy545 · Cited by 108
Self-citation
Conquering lung cancer: current status and prospects for the future
Pirker, R. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.02.005 · Cited by 101
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., de Marinis, F., Dumoulin, D. W., Reynolds, C. H., Theelen, W. S. M. E., Percent, I. J., Calderón, V. G., Johnson, M. L., Madroszyk, A., Garon, E. B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.004 · Cited by 103
Self-citation
Angiogenesis Inhibitors in NSCLC
Manzo, A., Montanino, A., Carillio, G., Costanzo, R., Sandomenico, C., Normanno, N., Piccirillo, M. C., Daniele, G., Perrone, F., Rocco, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102021 · Cited by 104
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Ren, S., Xiong, X., You, H., Shen, J., & Zhou, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689132 · Cited by 104
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 105
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
Nokihara, H., Lü, S., Mok, T. S. K., Nakagawa, K., Yamamoto, N., Shi, Y., Zhang, L., Soo, R. A., Yang, J. C., Sugawara, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx419 · Cited by 97
The impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 102
AACR Cancer Progress Report 2014
Arteaga, C. L., Adamson, P. C., Engelman, J. A., Foti, M., Gaynor, R. B., Hilsenbeck, S. G., Limburg, P. J., Lowe, S. W., Mardis, E. R., Ramsey, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2123 · Cited by 101
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials
Blumenthal, G. M., Zhang, L., Zhang, H., Kazandjian, D. G., Khozin, S., Tang, S. W., Goldberg, K. B., Sridhara, R., Keegan, P., & Pazdur, R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1029 · Cited by 98
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
Tamiya, M., Tamiya, A., Inoue, T., Kimura, M., Kunimasa, K., Nakahama, K., Taniguchi, Y., Shiroyama, T., Isa, S., Nishino, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192227 · Cited by 98
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016
Ladanie, A., Schmitt, A. M., Speich, B., Naudet, F., Agarwal, A., Pereira, T., Sclafani, F., Herbrand, A. K., Briel, M., Martín-Liberal, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.24406 · Cited by 103
The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
Chen, Y., Zheng, X., & Wu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.792691 · Cited by 104
AJRCCM : 100-Y ear A nniversary . The Shifting Landscape for Lung Cancer: Past, Present, and Future
Vachani, A., Sequist, L. V. D., & Spira, A. E. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0433ci · Cited by 97
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
Jiang, T., Qiao, M., Zhao, C., Li, X., Gao, G., Su, C., Ren, S., & Zhou, C. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2126-z · Cited by 93
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 93
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
Ando, Y., Hayashi, T., Sugimoto, R., Nishibe, S., Ito, K., Kawada, K., Ikeda, Y., Yamada, S., & Imaizumi, K. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00881-6 · Cited by 88
Immunotherapy-based combinations in metastatic NSCLC
Desai, A. P., & Peters, S. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102545 · Cited by 94
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
Hanna, N. H., Kaiser, R., Sullivan, R. N., Aren, O. R., Ahn, M., Tiangco, B., Voccia, I., von Pawel, J., Kovčin, V., Agulnik, J. S., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.011 · Cited by 88
Self-citation
Treatment of advanced squamous cell carcinoma of the lung: a review.
Derman, B. A., Mileham, K. F., Bonomi, P., Batus, M., & Fidler, M. J. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.07 · Cited by 90
Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study
Lim, S. H., Sun, J., Choi, Y., Kim, H. R., Ahn, S., Lee, J. Y., Lee, S., Ahn, J. S., Park, K., Kim, J. H., et al. (2016) · Cancer · doi:10.1002/cncr.30135 · Cited by 87
Self-citation
Recent advances in anti-angiogenic nanomedicines for cancer therapy
Bhattarai, P., Hameed, S., & Dai, Z. (2018) · Nanoscale · doi:10.1039/c7nr09612g · Cited by 90
Chemotherapy for Lung Cancer in the Era of Personalized Medicine
Lee, S. H. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0068 · Cited by 91
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
Shukuya, T., Yamanaka, T., Seto, T., Daga, H., Goto, K., Saka, H., Sugawara, S., Takahashi, T., Yokota, S., Kaneda, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00305-8 · Cited by 86
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
Garassino, M. C., Gelibter, A. J., Grossi, F., Chiari, R., Parra, H. J. S., Cascinu, S., Cognetti, F., Turci, D., Blasi, L., Bengala, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.025 · Cited by 85
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K. C., Florez, N., Gadgeel, S. M., Masters, G. A., Schenk, E. L., Schneider, B. J., Sequist, L. V. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02746 · Cited by 87
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
Lupo, G., Caporarello, N., Olivieri, M., Cristaldi, M., Motta, C., Bramanti, V., Avola, R., Salmeri, M., Nicoletti, F., & Anfuso, C. D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00519 · Cited by 83
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Petrylak, D. P., Tagawa, S. T., Kohli, M., Eisen, A. F., Canil, C., Sridhar, S. S., Spira, A. I., Yu, E. Y., Burke, J. M., Shaffer, D. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0218 · Cited by 82
Self-citation
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
Rulli, E., Ghilotti, F., Biagioli, E. C., Porcu, L., Marabese, M., D’Incalci, M., Bellocco, R., & Torri, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0302-8 · Cited by 86
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
Mazières, J., Lafitte, C., Ricordel, C., Greillier, L., Negre, E., Zalcman, G., Domblides, C., Madelaine, J., Bennouna, J., Mascaux, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01455 · Cited by 84
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Zamorano, J. L., Lancellotti, P., Muñoz, D. R., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0156 · Cited by 86
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Journal of UOEH · doi:10.7888/juoeh.40.173 · Cited by 80
MicroRNAs in non‐small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential
Petrek, H. E., & Yu, A. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.528 · Cited by 82
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Besse, B., Felip, E., Campelo, R. G., Cobo, M., Mascaux, C., Madroszyk, A., Cappuzzo, F., Hilgers, W., Romano, G. D., Denis, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.006 · Cited by 83
Self-citation
Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
Melosky, B. L., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., McLeod, D., & Hirsh, V. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8049 · Cited by 81
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer
Morgensztern, D., & Herbst, R. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2998 · Cited by 80
Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
Li, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.664853 · Cited by 79
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
Iwama, E., Zenke, Y., Sugawara, S., Daga, H., Morise, M., Yanagitani, N., Sakamoto, T., Murakami, H., Kishimoto, J., Matsumoto, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.021 · Cited by 81
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
Chiorean, E. G., Hurwitz, H. I., Cohen, R. B., Schwartz, J. D., Dalal, R., Fox, F. E., Gao, L., & Sweeney, C. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv144 · Cited by 78
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Remón, J., Besse, B., & Soria, J. (2017) · BMC Medicine · doi:10.1186/s12916-017-0819-3 · Cited by 81
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
Gregorc, V., Gaafar, R. M., Favaretto, A. G., Grossi, F., Jassem, J., Polychronis, A., Bidoli, P., Tiseo, M., Shah, R. N. H., Taylor, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30193-1 · Cited by 79
Self-citation
Immunosuppressive effects of vascular endothelial growth factor (Review)
Ribatti, D. (2022) · Oncology Letters · doi:10.3892/ol.2022.13489 · Cited by 85
Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer
Doebele, R. C., Spigel, D. R., Tehfe, M. A., Thomas, S. P., Reck, M., Verma, S., Eakle, J. F., Bustin, F., Goldschmidt, J. H., Cao, D., et al. (2014) · Cancer · doi:10.1002/cncr.29132 · Cited by 77
Self-citation
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer
Qiang, H., Chang, Q., Xu, J., Qian, J., Zhang, Y., Lei, Y., Han, B., & Chu, T. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03129-6 · Cited by 76
Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Gao, F., & Yang, C. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666191114110359 · Cited by 80
Cetuximab for treating non-small cell lung cancer
Mazzarella, L., Guida, A., & Curigliano, G. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1452906 · Cited by 79
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Papadopoulos, K. P., Kelley, R. K., Tolcher, A. W., Razak, A. R. A., Loon, K. V., Patnaik, A., Bedard, P. L., Alfaro, A. A., Beeram, M., Adriaens, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1221 · Cited by 74
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
Palma, G., Khurshid, F., Lu, K., Woodward, B., & Husain, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00237-5 · Cited by 72
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
Shiono, A., Kaira, K., Mouri, A., Yamaguchi, O., Hashimoto, K., Uchida, T., Miura, Y., Nishihara, F., Murayama, Y., Kobayashi, K., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12998 · Cited by 73
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Cortot, A. B., Audigier-Valette, C., Molinier, O., Moulec, S. L., Barlési, F., Zalcman, G., Dumont, P., Pouessel, D., Poulet, C., Fontaine-Delaruelle, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.022 · Cited by 72
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies
Shukuya, T., Mori, K. P., Amann, J. M., Bertino, E. M., Otterson, G. A., Shields, P. G., Morita, S., & Carbone, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.017 · Cited by 74
Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions
Caporarello, N., Lupo, G., Olivieri, M., Cristaldi, M., Cambria, M. T., Salmeri, M., & Anfuso, C. D. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7179 · Cited by 77
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
Barlési, F., Garon, E. B., Kim, D., Felip, E., Han, J., Kim, J.-H., Ahn, M., Fidler, M. J., Gubens, M. A., de Castro, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.016 · Cited by 69
Self-citation
Milestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 79
The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Jiang, S., Liang, H., Liu, Z., Zhao, S., Liu, J., Xie, Z., Wang, W., Zhang, Y., Han, B., He, J., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0838 · Cited by 71
Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer
Gallo, G., Vescio, G., Paola, G. D., & Sammarco, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112295 · Cited by 72
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
Nadal, E., Saleh, M. N., Ponce-Aix, S., Ochoa-de-Olza, M., Patel, S. P., Antonia, S. J., Zhao, Y., Gueorguieva, I., Man, M. Z., Estrem, S. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11153-1 · Cited by 70
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Fuchs, C. S., Tabernero, J. M., Tomášek, J., Chau, I., Melichar, B., Safran, H. P., Tehfe, M. A., Dumitru, F., Топузов, Э. Э., Schlittler, L. A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.293 · Cited by 69
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02245-z · Cited by 68
EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC
Meng, J., Chang, C., Chen, Y., Bi, F., Ji, C., & Liu, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s209441 · Cited by 67
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
New Treatment Options in Advanced Squamous Cell Lung Cancer
Paik, P. K., Pillai, R. N., Lathan, C. S., Alarcon, S. V., & Papadimitrakopoulou, V. A. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237829 · Cited by 66
Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)
Cosmai, L., Gallieni, M. A., Liguigli, W., & Porta, C. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0311-8 · Cited by 69
The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
Fong, A., Durkin, A., & Lee, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030586 · Cited by 50
Strategies targeting angiogenesis in advanced non-small cell lung cancer
Wang, J., Chen, J., Guo, Y., Wang, B., & Chu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17957 · Cited by 64
Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
Toyoda, T., Kamata, T., Tanaka, K., Ihara, F., Takami, M., Suzuki, H., Nakajima, T., Ikeuchi, T., Kawasaki, Y., Hanaoka, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000316 · Cited by 68
Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection
Ruiz-Ceja, K. A., & Chirino, Y. I. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.018 · Cited by 66
Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma
Kuribayashi, K., Funaguchi, N., & Nakano, T. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.174185 · Cited by 64
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment
Langer, C. J., Obasaju, C. K., Bunn, P. A., Bonomi, P., Gandara, D. R., Hirsch, F. R., Kim, E. S., Natale, R. B., Novello, S., Paz-Ares, L. G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.138 · Cited by 62
Self-citation
Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64
Self-citation
The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update
Villaruz, L. C., & Socinski, M. A. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0448-y · Cited by 64
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
Hong, S., Tan, M. H., Wang, S., Luo, S., Chen, Y., & Zhang, L. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1862-5 · Cited by 63
Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
Kato, R., Hayashi, H., Chiba, Y., Miyawaki, E., Shimizu, J., Ozaki, T., Fujimoto, D., Toyozawa, R., Nakamura, A., Kozuki, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000350 · Cited by 63
Interleukin-1 (IL-1) and the inflammasome in cancer
Prêtre, V., Papadopoulos, D., Regard, J. B., Pelletier, M. R., & Woo, J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155850 · Cited by 66
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Chon, K., Larkins, E. A., Chatterjee, S., Mishra-Kalyani, P. S., Aungst, S. L., Wearne, E., Subramaniam, S., Li, Y., Liu, J., Sun, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3713 · Cited by 61
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Li, Z., Wang, Y., Sun, Y., Wang, L., Li, X., Sun, L., He, Z., Yang, H., Wang, Y., Wang, Q., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00012-9 · Cited by 64
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
Zhao, S., Cheng, Y., Wang, Q. J., Li, X., Liao, J., Rodon, J. A., Meng, X., Luo, Y., Chen, Z., Wang, W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03638-2 · Cited by 67
Bevacizumab in advanced lung cancer: state of the art
Assoun, S., Brosseau, S., Steinmetz, C., Gounant, V., & Zalcman, G. (2017) · Future Oncology · doi:10.2217/fon-2017-0302 · Cited by 63
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Shi, Y., Wu, L., Yu, X., Xing, P., Wang, Y., Zhou, J., Wang, A., Shi, J., Hu, Y., Wang, Z., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12385 · Cited by 61
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies
Santoni, M., Guerra, F., Conti, A., Lucarelli, A., Rinaldi, S., Belvederesi, L., Capucci, A., & Berardi, R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.006 · Cited by 60
The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
Daum, S., Hagen, H., Naismith, E., Wolf, D. G. F., & Pircher, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.610903 · Cited by 60
Salvage treatment with apatinib for advanced non-small-cell lung cancer
Song, Z., Yu, X., Lou, G., Shi, X., & Zhang, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s113435 · Cited by 60
Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
Zhou, Q. W., Meng, X., Sun, L., Huang, D., Yang, N., Yu, Y., Zhao, M., Zhuang, W., Guo, R., Hu, Y., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.08.005 · Cited by 59
Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade
Eichten, A., Su, J., Adler, A. P., Zhang, L., Ioffe, E., Parveen, A. A., Yancopoulos, G. D., Rudge, J. S., Lowy, I., Lin, H. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1443 · Cited by 60
Albumin nanoparticles with synergistic antitumor efficacy against metastatic lung cancers
Kim, B., Seo, B., Park, S. H., Lee, C., Kim, J. O., Oh, K. T., Lee, E. S., Choi, H., & Youn, Y. S. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.06.039 · Cited by 59
Self-citation

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
Garon, E. B., Cao, D., Alexandris, E., John, W. J., Yurasov, S., & Pérol, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.007 · Cited by 40
Self-citation
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Pérol, M., Ciuleanu, T., Arrieta, O. G., Prabhash, K., Syrigos, K. N., Göksel, T., Park, K., Kowalyszyn, R. D., Pikiel, J., Czyżewicz, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba8006 · Cited by 17
Self-citation
A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Prabhash, K., Doval, D. C., Rangarajan, B., Somani, N., Pruthi, A., Dyachkova, Y., & Puri, T. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_159_21 · Cited by 3
Self-citation
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Yoh, K., Hosomi, Y., Kasahara, K., Yamada, K., Takahashi, T., Yamamoto, N., Nishio, M., Ohe, Y., Koue, T., Nakamura, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.019 · Cited by 110
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Bidoli, P., Cappuzzo, F., Favaretto, A. G., Alabiso, O., Tiseo, M., Chella, A., Gebbia, V., Pizzuti, L., Paz-Ares, L. G., Pérol, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv343.04 · Cited by 2
Self-citation

See all

Authors: Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
Affiliations: University of California, Los Angeles (US)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
Instituto Nacional de Cancerología (MX)
Tata Memorial Hospital (IN)
Sotiria General Hospital (GR)
Samsung Medical Center (KR)
Russian Cancer Research Center NN Blokhin (RU)
Charing Cross Hospital (GB)
University Hospital Heidelberg (DE)
Azienda Ospedaliera San Gerardo (IT)
Cancer Center of Kansas (US)
Gemeinschaftskrankenhaus Herdecke (DE)
Yonsei University Health System (KR)
Institutul Oncologic Bucuresti (RO)
City Clinical Oncology Center (RU)
German Center for Lung Research (DE)
Ospedale di Livorno (IT)
Eli Lilly (United States) (US)
Corresponding author: Garon, Edward B
ORCID: Garon, Edward B
Ciuleanu, Tudor-Eliade
Arrieta, Oscar
Prabhash, Kumar
Park, Keunchil
Gorbunova, Vera
Pikiel, Joanna
Thomas, Michael
Dakhil, Shaker
Kim, Joo-Hang
Grigorescu, Alexandru
Reck, Martin
Cappuzzo, Federico
Sashegyi, Andreas
Yurasov, Sergey
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-08
Volume: 384
Issue: 9944
Pages: 665-673
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(14)60845-x
OpenAlex: W2140980839
Cited by: 1,309
References: 35
Citations by year: 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
FWCI: 116.89
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
MeSH terms: Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks